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Hormone therapya b s t r a c t
Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR),
while up to 20% of BC show an overexpression/amplification of Human Epidermal Growth Factor
Receptor 2 (HER2). Around 50% of all HER2-overexpressing BC show the coexistence of both HER2 over-
expression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest
the existence of a cross-talk between their downstream pathways, which seem to affect the natural
history, response to therapy and outcome of patients affected by this subset of BC. Meta-analyses or
subgroup analysis of numerous neo-/adjuvant trials demonstrated significant clinical implications
deriving from ER/HER2 co-existence, consisting in a different pattern of relapse and dissimilar outcome
in response to anti-HER2 therapy. However, only two randomized trials in early disease and three in
advanced disease specifically addressed the issue whether a combined approach with both hormonal
and anti-HER2 therapy would have a better therapeutic impact in this subset of BC compared to the lone
anti-HER2 or hormonal therapies (HT). None of these trials demonstrated improvements in overall
survival, even though several efficacy end-points such as progression free survival, in advanced setting,
or pCR rates in neoadjuvant setting, often favored the combined hormonal and anti-HER2 therapeutic
approach. In the next few years, a certain number of ongoing randomized trials, both in neoadjuvant
and advanced setting, will evaluate the efficacy of new anti-HER2 drugs, T-DM1 and pertuzumab, in com-
bination with HT, helping to improve the therapeutic strategy for this specific subtype of breast tumors.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Approximately 75% of all breast cancers (BC) express estrogen
receptors (ER) and/or progesterone receptors (PgR) [1], while up
to 20% of BC show an overexpression/amplification of Human Epi-
dermal Growth Factor Receptor 2 (HER2). In nearly 50% of HER2
positive (+) BC, there is the coexistence of both expression of ER/
PgR and iperexpression/amplification of HER2 [2,3]. In vitro and
in vivo models suggested the existence of a cross-talk between
the two downstream pathways (Fig. 1) which affects the natural
history, response to therapy and outcome of patients affected by
this subset of BC. In this paper we will discuss the currentpreclinical and clinical evidence concerning the bidirectional cross-
talk between ER and HER2 pathways and the potential clinical
implications of this intriguing coexistence.An overview of HER2 and ER pathways
HER2 is a member of the HER family, which consists in 4 trans-
membrane tyrosine kinase receptors: EGFR/HER1, c-erbB2/HER2,
HER3 and HER4. HER2 functions as universal co-receptor for the
other HER family members and, when overexpressed or amplified,
constitutively stimulates tumor growth, invasiveness and survival
via activation of several signaling cascades, mostly MAPK and PI3K/
Akt pathways [4–6]. More specifically, HER2-EGFR dimers induce
proliferation and improve invasive functions, HER2 homodimers
alter cell polarity and HER2-HER3 dimers increase tumor cell
metabolic functions, favor cell survival, induce proliferation and
increase invasiveness [1–3]. Finally, HER2 overexpression also
results in an increased production of the rare DHER2 isoform with
Fig. 1. Simplified ER and HER2 signalings’ cross-talk. Estrogens (E) act via a non nuclear/non genomic activity and a nuclear/genomic activity. Non nuclear estrogen receptor
(ER) interacts directly or indirectly (e.g. via G proteins) with human epidermal growth factor receptor (HER)2/HER1-4 dimers activating their downstream kinase pathways
(e.g. Ras-MAPK and PI3K-Akt pathways), which in turn phosphorylate ER and other transcription factors (TFs) and coactivators/corepressors (CoA/R), modulating gene
expression. HER2 signaling pathways also reduce ER expression at both mRNA and protein levels. ER also promotes HER2, other tyrosine chinese receptors (TKR) and TKR
ligands’ gene expression. This bidirectional cross-talk leads to cancer cell cycle progression, proliferation, survival and invasiveness.
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gene for breast tumors, HER2 is also a relevant negative prognostic
factor [7] associated with decreased disease/event free survival
(DFS/EFS) and overall survival (OS) [8], however it is also the
molecular target of HER2-targeted agents such as trastuzumab,
pertuzumab, lapatinib and T-DM1. ER modulates the expression
of numerous genes. The binding of estrogen determines a receptor
dimerization, which regulates gene expression. ER can also
function as a co-regulator for other transcriptional factors. Several
tyrosine kinase receptors such as EGFR, IGF1 and HER2 may acti-
vate ER in a ligand independent manner, via phosphorylation,
determining an important cross-talk between ER and tyrosin
receptor kinase pathways [1]. Some studies also suggest a non-
transcriptional mechanism of action for ER, which can alter the
expression of several growth factors-dependent genes [1]. The
majority of BCs are driven in growth and survival by constitutively
activated ER, expressed in nearly 75% of all breast tumors [1].
HER2+ BC is a heterogeneous disease. In nearly 50% of them there
is also the ER and/or PgR expression (HR+) [2,3]. A study from the
Cancer Genome Atlas Network [9], based on genomic DNA copy
number arrays, DNA methylation, exome sequencing, mRNA
arrays, microRNA sequencing and reverse phase protein arrays,
confirmed, on a molecular basis, the existence of at least two
subtypes of HER2+ BC, as follows:
 HER2E-mRNA-subtype/HER2-clinically positive tumors, which
showed a significantly higher expression of a number of tyrosin
kinase receptors (RTKs), including HER2 itself and genes within
the HER2-amplicon.
 Luminal-mRNA-subtype/HER2-clinically positive tumors,
which showed higher expression of the typical Luminal genes,
including GATA3, BCL2 and estrogen receptor gene ESR1.
The coexistence of both HR and HER2 overactivated pathways
influences the natural history of disease and patients’ outcome.
In fact, data from prospective cohorts have demonstrated differentoutcome between the HR+/HER2+ and HR negative ()/HER2+
population with a distinct pattern of recurrence. The latter experi-
enced more relapses in the first five years, with brain rather than
bones as first site of recurrence [10,11]. A retrospective analysis
from the HERA trial of adjuvant trastuzumab also demonstrated
for the HR cohort a very high risk of early recurrence, in contrast
with HR+ disease, characterized by a relatively consistent risk of
relapse over time [12].Therapeutic implications of HER2 and ER pathways cross-talk:
preclinical evidences
The presence of both HR and HER2 amplified pathways seem to
impact on therapy efficacy. It is well known that patients with
higher levels of HER-2 had statistically significant lower levels of
HR than patients with lower levels of HER-2 [3]. Since levels of
expression of HR are directly correlated with response to hormone
therapy (HT) [3,13,14], the reduced effectiveness of hormonal
treatments usually experienced in this subset of patients compared
to HR+ HER2 negative breast cancers is not surprising at all. More-
over, several studies have provided numerous evidences that HER2
pathways may directly or indirectly contribute to the development
of resistance to HT. The currently identified mechanisms of
resistance are summarized below [15]:
 A HER-mediated activation of the PI3K/Akt/mTOR and p42/44
MAPK pathways induces a down-regulation of both ER and
PgR expression.
 The PAX2 transcriptional factor loss or deregulation seems to be
associated with the acquisition of a HER2-driven phenotype by
preventing the HER2 transcriptional repression by estrogen-ER
and tamoxifen-ER complexes.
 In BC cell lines some studies have shown a possible role for the
membrane ER in promoting an antiapoptotic effect through
EGFR, HER2, IGFR1 and their transduction pathways.
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development of several cases of HT resistance. Moreover, the ER
expression in HER2+ tumors may suggest the existence of a
cross-talk between ER and HER2 signaling pathways involved in
the development of resistance to anti-HER2 therapies [3], as indi-
cated by preclinical studies. In HR+/HER2+ cell lines a sustained
inhibition of HER2 with lapatinib or the combination of lapatinib
and trastuzumab was suddenly overcome by ER stimulation, which
become the primary controller of cancer survival and proliferation
[16,17].
Other preclinical data in HR+/HER2+ BC cell lines showed a
restoration of lapatinib or trastuzumab responsiveness with estro-
gen deprivation or by using fulvestrant [18].
Furthermore, in metastatic patients chronically exposed to tras-
tuzumab, HR tumors showed a sudden up-regulation of ER fol-
lowed by a decrease of response to anti-HER2 therapies [19].
Similar findings during anti-HER2 therapy were reported also in
other studies [20,21]. The increasing in HR signaling in HR+/
HER2+ tumors treated with lapatinib monotherapy in preclinical
models may suggest that HR positivity could be a marker of
HER2 target therapies sensitivity. Preclinical studies showed that
double blocking HER2 and ER by various combinations of lapatinib,
trastuzumab, pertuzumab and gefitinib with tamoxifen or ED (a
substance which mimics the effect aromatase inhibitors) induced
the best tumor response in mice carrying xenograft tumors with
amplification/overexpression of HER2 [22,23].
In a recent preclinical study, in HER2+ clinical BC specimens col-
lected in a lapatinib neoadjuvant trial, HER2 inhibition enhanced or
restored ER expression with parallel upregulation of PgR and the
antiapoptotic protein Bcl2, representing a potential mechanism
of survival and anti-HER2 resistance. Interestingly, the effective
inhibition of ER signaling with fulvestrant completely reverted lap-
atinib resistance in vitro. Finally, in a xenograft model, in presence
of restored ER expression, adding HT to anti-HER2 treatment sig-
nificantly delayed tumor progression [21]. These preclinical data
strongly suggest that a bi-directional cross-talk between ER and
HER2 signaling pathways may determine a reduced effectiveness
for both anti-HER2 targeted and HT.Therapeutic implications of HER2 and ER pathways cross-talk:
clinical evidences
Studies in the neoadjuvant setting showed a correlation
between anti-HER2 therapies activity and HR status. The CTneoBC
pooled analysis including 12 international neoadjuvant trials
clearly demonstrated an association between pCR and long-term
outcome in HER2+ BC, irrespective of HR status (EFS Hazard
Ratio/HR: 0.39; 95% CI: 0.31–0.50; OS HR: 0.34; 95% CI: 0.24–
0.47), even though the strength of the association was higher for
the HR subgroup (EFS HR: 0.25; 95% CI: 0.18–0.34; OS HR:
0.19; 95% CI: 0.12–0.31). HR-/HER2+ tumors receiving trastuzumab
(trast+) were the subgroup with a more favorable outcomes after
achieving pCR (EFS HR: 0.15; 95% CI: 0.09–0.27; OS HR: 0.08, 95%
CI: 0.03–0.22) compared to HR+/HER2+ trastuzumab untreated
(trast) or trast+(trast+ OS HR: 0.56; 95% CI: 0.23–1.37; trast
OS HR: 0.57; 95% CI: 0.31–1.04) and HR/HER2+ not receiving tras-
tuzumab (OS HR: 0.29; 95% CI: 0.17–0.50). Additionally, HR/HER2+
trast+ disease was the one with the highest percentage of pCR
achieved, compared to all BC subtypes and, more specifically
among all of the HER2+ BC subgroups (HRHER2 + trast + 50.3%
pCR vs HR + HER2 + trast+ 30.9% pCR vs HRHER2 + trast 30.2%
pCR vs HR + HER2 + trast 18.3% pCR) [24].
A recent meta-analysis from Von Minckwitz and colleagues [25]
including 7 randomized neoadjuvant trials reported a statistically
significant impact on prognosis for pCR in HR/HER2+, as oppositepCR did not correlate with prognosis in HR+/HER2+ tumors
(referred as Luminal B HER2+, in the paper), irrespective of trastu-
zumab treatment. Additionally, HER2+ non-luminal tumors
achieved pCR more frequently than luminal B HER2+ both treated
with chemotherapy plus trastuzumab (32.9% vs 22.2%, respec-
tively) and experienced better DFS than patients with luminal B
HER2+ disease (p < 0.02).
Recent neoadjuvant clinical trials in HER2+ disease (NeoALTTO,
NeoSphere, CALGB40601) also showed a different response rates to
anti-HER2 drugs in HR+ vs HR tumors. In NeoALTTO (lapatinib vs
trastuzumab vs lapatinib-trastuzumab), in-breast pCR were consis-
tently higher in HR than in HR+ disease treated with trastuzumab
(36.5% vs 22.7%), lapatinib (33.7% vs 16.1%) or with their combina-
tion (61.3% vs 41.6%) [26]. These results may be of prognostic rel-
evance, since achievement of pCR was associated with improved
EFS [27]. In NeoSphere trial (docetaxel-pertuzumab or trastuzu-
mab or both vs pertuzumab-trastuzumab) in-breast pCR was,
again, higher in HR (63.2%) disease rather than HR+ (26%) in
the docetaxel-trastuzumab-pertuzumab arm but also in the
chemo-free dual HER2 blockade arm (27.3% vs 5.9%) [28]. The
CALGB 40601 trial (lapatinib vs trastuzumab vs their combination,
all followed by weekly paclitaxel) failed to demonstrate a statisti-
cally significant difference in pCR rates among the experimental
arms. Anyway a molecular subtyping analysis was performed
before and after systemic therapy on tumor samples, allowing to
divide the clinical HER2+ tumors into all of the four major intrinsic
subtypes. Interestingly the in-breast pCR rates (overall result 46%)
was higher in the HER2-enriched/clinical HER2+ subtype (69% of
the responses) [29]. Results from these trials are summarized in
Table 1.
In adjuvant setting several studies demonstrated poorer out-
come for HR+/HER2+ BC patients compared to HR+/HER2 patients
undergone HT. Anyway some studies indicate no benefit or a
potentially detrimental effect in tamoxifen-treated patients, while
other failed to show similar results [30–35].
Retrospective analyses for the ATAC and BIG1-98 adjuvant aro-
matase inhibitors (AI) trials reported a worse clinical outcome in
HER2+ BCs, regardless of treatment type but failed to demonstrate
a clear interaction between HER2 status and type of HT on long-
term efficacy outcomes [36,37].
In a retrospective subgroup analysis of the HERA trial, in
patients with HR+/HER2+ tumors a slightly lower magnitude of
effect for adjuvant trastuzumab was observed between experi-
mental arm vs observational arm (% DFS events: 10.1% vs
14.4%; HR 0.68; 95% CI:0.51–0.89) compared to what happened
in HR/HER2+ tumors (% DFS events: 15.5% vs 23.5%; HR 0.62;
95% CI:0.5–0.77). Additionally, considering a different pattern
of relapse (earlier recurrences for HR, relatively higher risk of
recurrence over time for HR+), the efficacy of trastuzumab treat-
ment appeared to be more pronounced in first years of follow-up
for the HR cohort, and more consistent through time for HR+
cohort [12]. Also in a very recent retrospective study concerning
early HR+/HER2+ BC, adjuvant Trastuzumab improved both
relapse free survival (RFS) and breast cancer specific survival
(BCSS) (p < 0.0001 and p = 0.001, respectively), when added to
chemotherapy. However, the effect on BCSS in tumors expressing
both ER and PgR in more than 30% of cells failed to reach the
statistic significance (p = 0.26). Additionally, adjuvant Tras-
tuzumab failed to add a statistically significant improvement
for both endpoints (RFS and BCSS) in tumors with ER and PgR
overexpressed in more than 50% of cells (p = 0.09 and p = 0.16,
respectively). Furthermore, distinct patterns of relapse were also
observed between lower overexpressing and higher overexpress-
ing HR tumors, with the latter showing low and constant risk in
the first 5 years and a late increase beyond 5 years, with modest
trastuzumab effect [38].
Table 1
Neoadjuvant trials of anti-HER2 therapies in HR/HER2+ vs HR+ HER2+ breast cancer.
Trial Phase Scheme Results
NeoALTTO III Trastuzumab vs Lapatinib vs Trastuzumab + Lapatinib In-breast pCR in HR-/HER2 + vs HR+/HER2+:
 Trastuzumab arm: 36.5% vs 22.7%
 Lapatinib arm: 33.7% vs 16.1%
 Trast. + Lap. arm: 61.3% vs 41.6%
NeoSphere II Docetaxel ± Trastuzumab ± Pertuzumab vs Trastuzumab + Pertuzumab In-breast pCR in HR/HER2 + vs HR+/HER2+:
 Doc. ± Trast. ± Pert. arm: 63.2% vs 26%
 Trast.+Pert. arm: 27.3% vs 5.9%
CALGB40601 III Trastuzumab vs Lapatinib vs Trastuzumab + Lapatinib followed by weekly paclitaxel In-breast pCR:
 Overall result: 46%
 HER2-E/HER2clinically + subtype: 69%
pCR: pathologic complete response; HER2-E: HER2-enriched; HER2-clinically+: HER2 clinically positive.
Table 2
Clinical trials exploring the role of combined anti-HER2 with hormonal therapies.
Trial Phase Scheme Results p
TAnDEM III Anastrozole vs Anastrozole + Trastuzumab  median PFS/TTP: 2.4 vs 4.8 mts
 ORR: 7% vs 20%




EGF30008 III Letrozole vs Letrozole + Lapatinib  Median PFS: 3.0 vs 8.2 mts
 ORR: 15% vs 28%




eLEcTRA III Letrozole vs Letrozole + Trastuzumab  Median PFS: 3.3 vs 14.1 mts
 ORR: 13% vs 27%




mts: months; PFS: progression free survival; TTP: time to progression; ORR: overall response rate; CBR: clinical benefit rate.
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sensitivity to chemotherapy plus anti-HER2 therapy in HR
tumors, with significant benefit in PFS when a maintenance HT
was added to trastuzumab after chemotherapy in HR + HER2+ BC
[39]. In contrast, a retrospective observational study including
164 women affected by HER2+ tumors treated with trastuzumab-
based first line therapy, showed that patients with long-term clin-
ical benefit had a higher likelihood of having HR+ tumors. Anyway,
it may be relevant that the subgroup of HR+ patients had received
maintenance trastuzumab and/or HT after first-line, which could
have positively affected the outcome [40]. In another retrospective
study concerning metastatic BC, a cohort of all BC subtypes treated
with up to four lines of systemic therapy showed a better PFS, OS
and post progression survival (PPS) beyond first line treatment
for HER2+ tumors compared to the other BC subtypes (p < 0.0001
for all measures of outcome). These results seemed to be driven
mostly by the HR + HER2+ cohort performance (median PFS of
17.5 vs 8.1 months, median OS of 55.3 vs 26 c of 27.8 vs 14 months,
for HR+ HER2+ and HRHER2+ subset, respectively) [41].
A prospective observational study on a cohort of more than
1000 HER2+ BC patients showed that in HR+/HER2+ tumors, the
dual targeting of HR and HER2, with or without chemotherapy,
was clearly associated with more prolonged PFS and OS compared
to anti-HER2 treatment alone [42]. All of the above mentioned data
consistently showed a different response to anti-HER2 or HT in
patients with a HER2+ BC according to HR status, hinting that ER
may constitute an escape pathway for tumors treated with anti-
HER2 agents and vice versa. Therefore, combining HT with anti-
HER2 therapy may represent a promising strategy to overcome
both endocrine and anti-HER2 resistance.
Combining HT with anti-HER2 therapies: current clinical
evidence
Only two trials in early disease and three trials in advanced dis-
ease addressed the issue whether a combined approach with both
HT and anti-HER2 therapy would have a better therapeutic impactin HR+/HER2+ BC compared to the conventional combination of
chemotherapy with anti-HER2 targeted agents. The three
advanced-setting trials compared a first-line therapy with an AI
to an experimental arm with a combination of the AI and lapatinib
or trastuzumab (table 2). The TAnDEM trial showed a median PFS/
time-to-progression (TTP) of 2.4 months for the AI (anastrozole)
arm compared to the experimental arm (anastrozole/trastuzumab)
4.8 months (p = 0.0016), with an overall response rate (ORR) of 7%
vs 20% and a clinical benefit rate (CBR) of 28% vs 43%, respectively
[43]. Interestingly, nearly 15% of patients who received trastuzu-
mab plus anastrozole did not experience disease progression for
at least 2 years, suggesting that this combination is highly effective
at least in a subgroup of patients. The EGF 30008 trial showed a
median PFS of 3.0 months for the letrozole arm vs 8.2 months for
the letrozole-lapatinib arm (p = 0.019). The ORR was 15% and
28%, and the CBR was 29% and 48%, for letrozole arm compared
to letrozole-lapatinib arm [44]. The eLEcTRA trial showed a median
PFS of 3.3 months for the letrozole arm vs 14.1 months for the
letrozole-trastuzumab arm (p = 0.23); the ORR was 13% vs 27%
and the CBR was 39% vs 65%, respectively [45]. None of these trials
demonstrated a clear benefit in terms of OS [43–45]. On the basis
of these results, several guidelines [46–48] recommended the use
of a combination of trastuzumab or lapatinib in combination with
an AI as a first-line option treatment for postmenopausal women
with HR+ HER+ BC, if chemotherapy is not clearly indicated. How-
ever, the standard clinical practice has been dramatically influ-
enced by the recent CLEOPATRA [49] and EMILIA [50] trials. The
first one demonstrated a significant increase in both PFS (18.7 vs
12.4 months, HR 0.68, 95% CI: 0.58–0.80; p < 0.001) and OS (56.5
vs 40.8 months, HR 0.68, 95% CI: 0.56–0.84; p < 0.001) with the
combination of trastuzumab, pertuzumab and docetaxel as com-
pared to trastuzumab and docetaxel in first-line therapy of
advanced HER2+ BC. Subgroup analysis failed to show a differential
impact based on HR status. The EMILIA compared the novel trastu-
zumab conjugated with the chemotherapic DM1 to lapatinib com-
bined to capecitabine for the treatment of advanced HER2+ BC in
second line or more. The experimental arm was superior in both
Table 3
Ongoing clinical trials evaluating the combination of new anti-HER2 treatments combined with hormone therapy.
Trial Phase Scheme Primary End-point
ADAPT HER2+/HR+ II TDM1 + TAM/AI vs TDM1 vs Trastuzumab + TAM/AI pCR
PER-ELISA II Trastuzumab + Pertuzumab + Letrozole pCR
PERTAIN II Trastuzumab + Pertuzumab + AI vs Trastuzumab + AI PFS
DETECT V III Trastuzumab + Pertuzumab + CT vs Trastuzumab + Pertuzumab + HT Number of participants with adverse events
3GCC II Trastuzumab + Pertuzumab vs Trastuzumab + Pertuzumab + Eribulin vs
Trastuzumab + Pertuzumab + HT
ORR
HT: hormonal therapy; CT: chemotherapy; TAM: Tamoxifen; AI: aromatase inhibitor.
24 F. Schettini et al. / Cancer Treatment Reviews 46 (2016) 20–26PFS (9.6 vs 6.4 months, HR 0.65; 95% CI: 0.55–0.77; p < 0.001), OS
(30.9 vs 25.1 months, HR 0.68, 95% CI: 0.55–0.85; p < 0.001) and
ORR (43.6% vs 30.8%; p < 0.001). Significantly, none of the two trials
tested the novel anti-HER2 therapy combined with HT, therefore
the current standard of care for metastatic HER2+ BC consists of
trastuzumab combined with pertuzumab and a taxane for first line
and TDM1 alone, starting from second line or as possible first-line
option in patients who experienced a disease relapse within six
months of adjuvant therapy.
In early disease two small phase II neoadjuvant trials provided
some evidences that double blocking HER2 and HR pathways,
without adding chemotherapy, may result in an effective strategy.
The TBCRC023 compared lapatinib plus trastuzumab, adding letro-
zole ± GnRH analoge in ER+ patients, for 12 weeks vs 24 weeks.
pCR rates were higher in the 24 weeks arm (24.2% vs 12.2%) mostly
thanks to the results in the ER+ subgroup (33.2% vs 8.7%), while
pCR rates were quite similar for the ER patients, suggesting a
more potent effect for the association of HT and anti-HER2 therapy
[51]. The TBCRC006 compared lapatinib vs trastuzumab, adding
letrozole ± GnRH in HR+ patients, for 12 weeks. The overall pCR
was 27% (21% in ER+ and 36% in ER patients) [52].Ongoing trials and future perspectives
The overall clinical evidences concerning the efficacy of a com-
bined Hormonal/anti-HER2 therapy approach are interesting and
definitely worthy of further study. In this perspective, several
recent clinical trials have been studying the combination of the
novel anti-HER2 drugs TDM1 and pertuzumab with HT both in
neoadjuvant and advanced setting (Table 3).
The ADAPT trial for HER2+/HR+ BC is the first one to explore in
neoadjuvant setting the efficacy of dual targeting HER2 and HR
with one of the two novel anti-HER2 drugs recently approved in
advanced BC. Three-hundred-eighty patients received neoadjuvant
therapy with T-DM1 + tamoxifen (TAM) or AI (arm A) vs T-DM1
alone (arm B) vs trastuzumab + TAM or AI (arm C). After surgery,
patients were to receive standard adjuvant treatment
with anthracycline, taxane and trastuzumab. The interim analysis
on 130 patients showed an overall pCR rate of 30.8% (pCR arm A
40.5% vs 45.8% arm B vs 6.7% arm C). The difference between either
arm A or B vs C was statistically significant (p < 0.001), despite no
significant difference between arm A vs B. Interestingly, explora-
tory analysis suggests benefit of adding HT to T-DM1 only in pre-
menopausal (pCR: 28.6% for T-DM1 vs 47.6% for T-DM1 + HT)
rather than postmenopausal setting (pCR: 64.3% vs 50%) [53]. How-
ever, an impact on these findings may be the result of both differ-
ent HT options (Tam vs AI) and prematurity of results. In fact, most
recent data presented at San Antonio Breast Cancer Symposium
2015 failed to show a sustained difference between the pCR
achieved in T-DM1 vs T-DM1 + HT arms (overall pCR 41% vs
41.5%, respectively; 44.1% vs 45.0% pCR in postmenopausal subset;
37.9% vs 38.1% pCR in premenopausal subset) [54]. Final data set is
required to further validate these results. Noteworthy, anotherphase II neoadjuvant trial (PER-ELISA) is currently recruiting
participants and will test the efficacy of the combination of trastu-
zumab, pertuzumab and letrozole [55]. Rimawi and colleagues
have been conducting since 2012 the randomized phase II trial
PERTAIN, exploring the combination of an AI with trastuzumab
and pertuzumab vs an AI with trastuzumab in first line treatment
of HR+/HER2+ metastatic BC (MBC) in postmenopausal setting
[56]. The DETECT V/CHEVENDO trial is a randomized phase III
study which aims to compare the combination of trastuzumab,
pertuzumab and a chemotherapy drug (docetaxel, paclitaxel, cape-
citabine or vinorelbine) with the combination of trastuzumab, per-
tuzumab and HT (tamoxifen, fulvestrant, letrozole or anastrozole).
It is an ongoing trial currently recruiting participants [57]. Finally,
the phase II 1303GCC trial will compare trastuzumab in combina-
tion with pertuzumab alone vs trastuzumab, pertuzumab and
eribuline vs trastuzumab, pertuzumab and HT (anastrozole or ful-
vestrant) in locally advanced or metastatic BC affecting patients
aged 60 or more [58]. Definitive results from all of these trials will
provide fundamental data concerning the efficacy and tolerability
of the combination of HT with novel anti-HER2 drugs T-DM1 and
pertuzumab which, if positive, although not exhaustive, may help
redefining the standard therapeutic approaches in HR+/HER2+ BC.Conclusions
Since compelling evidence concerning activity for hormonal/
anti-HER2 combination therapy has partially arisen in the setting
of both early and advanced HR+/HER2+ BC, future research should
be focused on comparing the current standard of care for HER2+
BC, which usually contains also chemotherapic drugs, to the asso-
ciation of hormonal and HER2 blockade therapy. In this perspec-
tive, the ongoing trials are crucial, but further phase III
randomized controlled trials using T-DM1 as control arm or adju-
vant/neoadjuvant trials experimenting both pertuzumab-
trastuzumab combination or T-DM1 as control arm are needed to
help addressing the issue. In fact, the shift to a more complex tar-
geted therapy strategy, oriented to contrast both estrogen and
HER2 pathways, may help obtaining adequate results with a con-
venient lower toxicity, compared to standard chemotherapy
drugs-containing regimens, helping to delay their use.Authors’ contributions
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